{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:05:18Z","timestamp":1791255918738,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204304"],"award-info":[{"award-number":["82204304"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019014","name":"Chengdu Municipal Science and Technology Program","doi-asserted-by":"publisher","award":["2022YF05-01626-SN"],"award-info":[{"award-number":["2022YF05-01626-SN"]}],"id":[{"id":"10.13039\/501100019014","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Youth Innovation Project of Sichuan Medical Association","award":["Q22006"],"award-info":[{"award-number":["Q22006"]}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2024NSFSC0197"],"award-info":[{"award-number":["2024NSFSC0197"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2023NSFSC1678"],"award-info":[{"award-number":["2023NSFSC1678"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific and Technological Innovation Team for Qinghai-Tibetan Plateau Research in Southwest Minzu University","award":["2024CXTD15"],"award-info":[{"award-number":["2024CXTD15"]}]},{"DOI":"10.13039\/501100018927","name":"Southwest Minzu University","doi-asserted-by":"publisher","award":["RQD2022033"],"award-info":[{"award-number":["RQD2022033"]}],"id":[{"id":"10.13039\/501100018927","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Personalized Drug Therapy Key Laboratory of Sichuan Province","award":["2022YB01"],"award-info":[{"award-number":["2022YB01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-024-02745-5","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T08:02:39Z","timestamp":1723276959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A bioinspired supramolecular nanoprodrug for precision therapy of B-cell non-Hodgkin\u2019s lymphoma"],"prefix":"10.1186","volume":"22","author":[{"given":"Qixiong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,10]]},"reference":[{"key":"2745_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrc1589","volume":"5","author":"R Kuppers","year":"2005","unstructured":"Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251\u201362.","journal-title":"Nat Rev Cancer"},{"key":"2745_CR2","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/annonc\/mdy092","volume":"29","author":"S Makita","year":"2018","unstructured":"Makita S, Tobinai K. Antibody therapy targeting CD19 for B-cell non-Hodgkin\u2019s lymphoma. Ann Oncol. 2018;29:1086\u20139.","journal-title":"Ann Oncol"},{"key":"2745_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-023-01488-4","volume":"16","author":"X Liu","year":"2023","unstructured":"Liu X, Zhao J, Guo X, Song Y. CD20 x CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting. J Hematol Oncol. 2023;16:90.","journal-title":"J Hematol Oncol"},{"key":"2745_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00262-002-0347-6","volume":"52","author":"P Chinn","year":"2003","unstructured":"Chinn P, Braslawsky G, White C, Hanna N. Antibody therapy of non-Hodgkin\u2019s B-cell lymphoma. Cancer Immunol Immunother. 2003;52:257\u201380.","journal-title":"Cancer Immunol Immunother"},{"key":"2745_CR5","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.1016\/S1470-2045(13)70450-9","volume":"14","author":"D Tan","year":"2013","unstructured":"Tan D, Tan SY, Lim ST, Kim SJ, Kim WS, Advani R, Kwong YL. Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:e548-561.","journal-title":"Lancet Oncol"},{"key":"2745_CR6","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.leukres.2013.05.004","volume":"37","author":"J Lukenbill","year":"2013","unstructured":"Lukenbill J, Kalaycio M. Fludarabine: a review of the clear benefits and potential harms. Leuk Res. 2013;37:986\u201394.","journal-title":"Leuk Res"},{"issue":"Suppl 2","key":"2745_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/10428199409052689","volume":"14","author":"V Gandhi","year":"1994","unstructured":"Gandhi V, Huang P, Plunkett W. Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias. Leuk Lymphoma. 1994;14(Suppl 2):3\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2745_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","volume":"24","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, Walewska R, Furtado M, Preston G, Neilson JR, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:535\u201352.","journal-title":"Lancet Oncol"},{"key":"2745_CR9","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.31557\/APJCP.2021.22.5.1639","volume":"22","author":"M Mehdizadeh","year":"2021","unstructured":"Mehdizadeh M, Parkhideh S, Salari S, Hajifathali A, Rezvani H, Mabani M. Adverse effects of busulfan plus cyclophosphamide versus busulfan plus fludarabine as conditioning regimens for allogeneic bone marrow transplantation. Asian Pac J Cancer Prev. 2021;22:1639\u201344.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2745_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3109\/1061186X.2013.878942","volume":"22","author":"NK Mittal","year":"2014","unstructured":"Mittal NK, Bhattacharjee H, Mandal B, Balabathula P, Thoma LA, Wood GC. Targeted liposomal drug delivery systems for the treatment of B cell malignancies. J Drug Target. 2014;22:372\u201386.","journal-title":"J Drug Target"},{"key":"2745_CR11","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/molecules27041310","volume":"27","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Lin W, Zhu L. Targeted drug delivery for the treatment of blood cancers. Molecules. 2022;27:1310.","journal-title":"Molecules"},{"key":"2745_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-021-01134-x","volume":"14","author":"Y Liu","year":"2021","unstructured":"Liu Y, Zhou X, Wang X. Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. J Hematol Oncol. 2021;14:125.","journal-title":"J Hematol Oncol"},{"key":"2745_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-immunol-102419-035900","volume":"38","author":"S Duan","year":"2020","unstructured":"Duan S, Paulson JC. Siglecs as immune cell checkpoints in disease. Annu Rev Immunol. 2020;38:365\u201395.","journal-title":"Annu Rev Immunol"},{"key":"2745_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40164-023-00454-7","volume":"12","author":"J Xu","year":"2023","unstructured":"Xu J, Luo W, Li C, Mei H. Targeting CD22 for B-cell hematologic malignancies. Exp Hematol Oncol. 2023;12:90.","journal-title":"Exp Hematol Oncol"},{"key":"2745_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrd4009","volume":"12","author":"A Mullard","year":"2013","unstructured":"Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013;12:329\u201332.","journal-title":"Nat Rev Drug Discov"},{"key":"2745_CR16","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.3390\/jcm10163556","volume":"10","author":"JL Stokke","year":"2021","unstructured":"Stokke JL, Bhojwani D. Antibody-drug conjugates for the treatment of acute pediatric leukemia. J Clin Med. 2021;10:3556.","journal-title":"J Clin Med"},{"key":"2745_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24:20\u20138.","journal-title":"Nat Med"},{"key":"2745_CR18","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-18-3784","volume":"25","author":"S Ramakrishna","year":"2019","unstructured":"Ramakrishna S, Highfill SL, Walsh Z, Nguyen SM, Lei H, Shern JF, Qin H, Kraft IL, Stetler-Stevenson M, Yuan CM, et al. Modulation of target antigen density improves CAR T-cell functionality and persistence. Clin Cancer Res. 2019;25:5329\u201341.","journal-title":"Clin Cancer Res"},{"key":"2745_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.carres.2021.108376","volume":"507","author":"K Mindler","year":"2021","unstructured":"Mindler K, Ostertag E, Stehle T. The polyfunctional polysialic acid: a structural view. Carbohydr Res. 2021;507: 108376.","journal-title":"Carbohydr Res"},{"key":"2745_CR20","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/j.apsb.2021.05.002","volume":"11","author":"Y Shi","year":"2021","unstructured":"Shi Y, Lu A, Wang X, Belhadj Z, Wang J, Zhang Q. A review of existing strategies for designing long-acting parenteral formulations: focus on underlying mechanisms, and future perspectives. Acta Pharm Sin B. 2021;11:2396\u2013415.","journal-title":"Acta Pharm Sin B"},{"key":"2745_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0167-4838(95)00227-8","volume":"1293","author":"AI Fernandes","year":"1996","unstructured":"Fernandes AI, Gregoriadis G. Synthesis, characterization and properties of sialylated catalase. Biochim Biophys Acta. 1996;1293:90\u20136.","journal-title":"Biochim Biophys Acta"},{"key":"2745_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0378-5173(01)00603-2","volume":"217","author":"AI Fernandes","year":"2001","unstructured":"Fernandes AI, Gregoriadis G. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. Int J Pharm. 2001;217:215\u201324.","journal-title":"Int J Pharm"},{"key":"2745_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105241","volume":"145","author":"Y Kou","year":"2020","unstructured":"Kou Y, Feng R, Chen J, Duan L, Wang S, Hu Y, Zhang N, Wang T, Deng Y, Song Y. Development of a nattokinase-polysialic acid complex for advanced tumor treatment. Eur J Pharm Sci. 2020;145: 105241.","journal-title":"Eur J Pharm Sci"},{"key":"2745_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0304-4165(03)00116-8","volume":"1622","author":"S Jain","year":"2003","unstructured":"Jain S, Hreczuk-Hirst DH, McCormack B, Mital M, Epenetos A, Laing P, Gregoriadis G. Polysialylated insulin: synthesis, characterization and biological activity in vivo. Biochim Biophys Acta. 2003;1622:42\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"2745_CR25","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s10529-010-0382-x","volume":"32","author":"JR Wu","year":"2010","unstructured":"Wu JR, Lin Y, Zheng ZY, Lin CC, Zhan XB, Shen YQ. Improvement of the CuZn-superoxide dismutase enzyme activity and stability as a therapeutic agent by modification with polysialic acids. Biotechnol Lett. 2010;32:1939\u201345.","journal-title":"Biotechnol Lett"},{"key":"2745_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/hae.13878","volume":"26","author":"A Tiede","year":"2020","unstructured":"Tiede A, Allen G, Bauer A, Chowdary P, Collins P, Goldstein B, Jiang HJ, K\u04e7ck K, Takacs I, Timofeeva M, et al. SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A. Haemophilia. 2020;26:47\u201355.","journal-title":"Haemophilia"},{"key":"2745_CR27","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1084\/jem.20011783","volume":"195","author":"S Kelm","year":"2002","unstructured":"Kelm S, Gerlach J, Brossmer R, Danzer CP, Nitschke L. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. J Exp Med. 2002;195:1207\u201313.","journal-title":"J Exp Med"},{"key":"2745_CR28","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1002\/anie.202005934","volume":"60","author":"S Hong","year":"2021","unstructured":"Hong S, Yu C, Wang P, Shi Y, Cao W, Cheng B, Chapla DG, Ma Y, Li J, Rodrigues E, et al. Glycoengineering of NK cells with glycan ligands of CD22 and selectins for B-cell lymphoma therapy. Angew Chem Int Ed Engl. 2021;60:3603\u201310.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2745_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.actbio.2022.06.033","volume":"149","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Li S, Guo K, Yin X, Tong R. Polysialylated nanoinducer for precisely enhancing apoptosis and anti-tumor immune response in B-cell lymphoma. Acta Biomater. 2022;149:321\u201333.","journal-title":"Acta Biomater"},{"key":"2745_CR30","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jconrel.2020.07.036","volume":"326","author":"S Li","year":"2020","unstructured":"Li S, Shan X, Wang Y, Chen Q, Sun J, He Z, Sun B, Luo C. Dimeric prodrug-based nanomedicines for cancer therapy. J Control Release. 2020;326:510\u201322.","journal-title":"J Control Release"},{"key":"2745_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1021\/acsami.1c20031","volume":"14","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Li S, Bai L, Yu D, Li H, Tong R. Self-delivery janus-prodrug for precise immuno-chemotherapy of colitis-associated colorectal cancer. ACS Appl Mater Interfaces. 2022;14:297\u2013306.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2745_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jconrel.2022.04.026","volume":"348","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Li S, Ren J, He X, Shi H, Zhang F, Li H, Tong R. ROS-triggered nanoinducer based on dermatan sulfate enhances immunogenic cell death in melanoma. J Control Release. 2022;348:22\u201333.","journal-title":"J Control Release"},{"key":"2745_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jconrel.2019.10.054","volume":"316","author":"S Li","year":"2019","unstructured":"Li S, Xie A, Li H, Zou X, Zhang Q. A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease. J Control Release. 2019;316:66\u201378.","journal-title":"J Control Release"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02745-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-024-02745-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02745-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T20:20:00Z","timestamp":1723321200000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-024-02745-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2745"],"URL":"https:\/\/doi.org\/10.1186\/s12951-024-02745-5","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,10]]},"assertion":[{"value":"19 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was approved by the ethics committee of Sichuan Academy of Medical Science & Sichuan Provincial People\u2019s Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and agree this version be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"475"}}